You and that study! Enough.

Got it and makes sense.

I look at this topic from a commonsense perspective. If doctors had to worry about patent infringement when prescribing medicine, there would be very few prescriptions issued and lots of dying patients for lack of readily available medication.

Capt he’s a wolf in sheep’s clothing.

You need to get off of this need for study to confirm Reduce-it results- geez.

From AI:
Authorized generic drugs have been a profitable strategy for pharmaceutical companies. They are essentially the same as the brand-name product in dosage form, safety, strength, route of administration, quality, performance characteristics, and intended use, but are marketed without the brand name and typically at a lower price.

The profitability of authorized generics is influenced by several factors:

Demand: There’s a rising demand for generic drugs due to increasing healthcare costs1.

Supply Chain: Generics manufacturers often outsource production to less expensive markets to remain profitable, though this can introduce quality and supply chain risks1.

Market Dynamics: The generics market faces a cycle of increased supply leading to reduced prices, which can affect profitability. However, strategies like mergers and acquisitions, supply chain redesign, and developing higher-value generics can help companies maintain profitability1.

In 2015, research suggested that for every dollar invested in authorized generics, companies could see a return of $502. While this figure is from 2015 and the market dynamics may have changed, it indicates that authorized generics have been a highly profitable approach in the past.

Looking ahead, the generics industry is expected to continue growing, with revenues projected to reach $99 billion by 20263. This suggests that there is still significant profit potential in the generics market, including for authorized generics.

Deranged? Who do you see when you look in a mirror?

Takes one to know one they say but I’m good, don’t need them. And you?

“Would you like another helping of blue pills?”

What the heck? SMH.

Many thanks Capt. Very encouraging trend even though still a long ways to go before rev is meaningful.

Thanks Capt. Very interesting and offers some hope for increasing the value of V.

Capt. Ignore idiots like this dude. Most of us appreciate and look forward to your weekly charts and commentary.

Wished mine worked for you too, but no luck.

Capt the $81.88 average would be accurate only if the discount applied for the full Q2 period. If discounting started somewhere within the quarter, and assuming the same discount was offered for all of Q3, the average will be lower than $81.88 for Q3. Hopefully not but my expectation is for less.

Capt if $88 is the average, then wouldn’t it be 807,588 x 88 = 71,067,744?

I have no trust in the US legal system and wouldn’t bet a dime that NWBO will get justice in this case. Being a long term investor in Amarin (Amrn) and witnessing with disgust, a liberal judge (invalidate) give generics many of their patents and destroy $7 billion in market value in one swoop, was just sickening to all long investors.

So, I have no expectations of a favorable result here. These crooks have extremely long corrupting ($) tentacles, that are entrenched to the abyss in the stock market.

From Stocktwits:

http://stocktwits.com/DoMoreCharity/message/546320264

FYI Linda Powers is Chairwoman of NWBO, not Dr. L.L.

V’s scripts were 234% greater than GL’s and 394% > DRL’s (highest GV script). Hope this strong and positive variance continues.

Tal, no worries.

Thanks Tal. However my understanding is that Mediation and Arbitration is different. Looks like the Court ordered Mediation. With Mediation, the two parties have to try to agree a solution, the mediator does not have power to decide vs Arbitration, the Arbitrator decides, much like a judge.

"What's holding steady..."

Your constant paid for bashing is holding steady. Would love to see your face when you wake up one morning, in the not too distant future, to BO news!

Agreed, appointment of a mediator indicates Dr Reddy’s case is weak - not worth the Court’s time with Lawyers and Judge.

Capt. thanks for this wonderful service you provide to us long investors. I really look forward to and appreciate your tracking reports every week.

@situ, if you are correct, that is a 19.17% increase month on month - very strong growth.

I have you on ignore but for some reason I’m still seeing your annoying posts!

@Whal "Why waste your time selling brand V in the US for $81.65 a mth ( Capts data ) when you can sell it for around $124 a mth ( from memory ...Capts data ) in the UK."

Are you suggesting Amarin should throw in the towel and give up its $65M quarterly sales in the US?

“I'll be back in a few years to say I told you so.”

Good riddance!

@canam, Amarin could have or received an offer that was / is not worth accepting or is being negotiated. The Board can’t announce when they are in negotiations. We just won’t know until they actually announce that they have accepted an offer that is deemed in the best interest of shareholders.

I agree it’s frustrating to not hear anything but it doesn’t mean there’s no interest or approaches made by BP. Hopefully we’ll wake up one day with an announced offer that exceeds our expectation.

@canam Quote: If AMRN was worth anything, to a BP, they'd have an offer. They haven't.

And your source of this certain statement is? How do you know what's going on behind closed doors?

@BB, I feel the same but is it that only us retail investors are paying attention, why the SP is less than a dollar? Kinda feels like we are very early invested, like those investors in Amazon in 2001, when the company only sold books, the SP was under a $1 and most people didn’t see Amazon potential.

Time will tell if we were very savvy / super smart AMZN like investors.

Great find and work Capt. Truly appreciate all that you selflessly do for shareholders.

@JRoon. I wholeheartedly agree!

@johnancoque and you really believe Denner plan is continue with ‘go it alone’? They are just continuing BAU while working on selling the company. Do you really expect Denner to come out and say to shareholders “Okay we are going to sell this company?

I was invested in NFLX for circa 5 years, got tired of waiting and sold at $60 ish for a few k profit. Six month later the stock went to the moon, I believe reaching $300+. My impatience got the best of me and I will not make that mistake with AMRN. Yes, been in Amrn since 2013, so I understand your cynicism.

Not disagreeing with your view, just saying the Board of Publicly traded company has to operate within corporate and regulatory rules. For e.g. they can’t say “we are negotiating a sale with a number of parties and believe the final price will be x. Yes, some flaunt the rules and get away with it - corrupted regulators? FINRA comes to mind.

A company has to be careful not to be accused of pumping its stock. Therefore not all actions behind closed doors can or should be disclosed to shareholders/potential shareholders, until appropriate. The stock market takes from the impatient and gives to the patient.

@could, if any buyout / partnership discussions have started, Sarissa wouldn’t be allowed to invest more, otherwise = insider trading. If they do buy more shares, that would signal no BO / partnership discussions in progress.

Idiot!

@ram, no video link.